European Union - English - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - eptifibatide - angina, unstable; myocardial infarction - antithrombotic agents - integrilin is intended for use with acetylsalicylic acid and unfractionated heparin.integrilin is indicated for the prevention of early myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction with the last episode of chest pain occurring within 24 hours and with ecg changes and / or elevated cardiac enzymes.patients most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early percutaneous transluminal coronary angioplasty (ptca).

Canada - English - Health Canada

merck canada inc - eptifibatide - solution - 0.75mg - eptifibatide 0.75mg - platelet aggregation inhibitors

Canada - English - Health Canada

merck canada inc - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - eptifibatide - injection - 2 mg/ml - eptifibatide 2 mg/ml

Singapore - English - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - eptifibatide - injection - 0.75 mg/ml - eptifibatide 0.75 mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - eptifibatide 0.75 mg/ml - solution for injection - 0.75 mg/ml - active: eptifibatide 0.75 mg/ml excipient: citric acid monohydrate water for injection - integrilin is indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction (chest pain with stsegment depression >0.5 mm or definitive t-wave inversion >1 mm or transient st-segment elevation >0.5 mm of less than 30 minutes or persistent st-segment elevation >0.5 mm not requiring reperfusion therapy or thrombolytic agents, or chest pain in patients without persistent st-segment elevation with ck-mb greater than the upper limit of normal). integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. patients with unstable angina (ua) or non-q-wave myocardial infarction (nqmi) who are most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first three to four days after onset of acute angina symptoms, including for instance those that are likely to undergo an early pci. integrilin is intended for use with aspirin, heparin and clopidigrel.

New Zealand - English - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - eptifibatide 2 mg/ml - solution for injection - 2 mg/ml - active: eptifibatide 2 mg/ml excipient: citric acid monohydrate water for injection - integrilin is indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction (chest pain with stsegment depression >0.5 mm or definitive t-wave inversion >1 mm or transient st-segment elevation >0.5 mm of less than 30 minutes or persistent st-segment elevation >0.5 mm not requiring reperfusion therapy or thrombolytic agents, or chest pain in patients without persistent st-segment elevation with ck-mb greater than the upper limit of normal). integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. patients with unstable angina (ua) or non-q-wave myocardial infarction (nqmi) who are most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first three to four days after onset of acute angina symptoms, including for instance those that are likely to undergo an early pci. integrilin is intended for use with aspirin, heparin and clopidigrel.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - eptifibatide - solution for injection - 2mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - eptifibatide - solution for infusion - 750microgram/1ml

Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd. - eptifibatide - solution for infusion - 0,75mg/ml